2-Methyl-6-(phenylethynyl) pyridine (MPEP) reverses maze learning and PSD-95 deficits in Fmrl knock-out mice

Frontiers in Cellular Neuroscience

Volumn 8, Issue MAR, 2014, Pages

  Gandhi, Réno M ^a   Kogan, Cary S ^a   Messier, Claude ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

2 Methyl 6 (phenylethynyl) pyridine; Fragile X syndrome; Hebb williams mazes; Post synaptic density 95; Western blot

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL) PYRIDINE; BETA TUBULIN; FRAGILE X MENTAL RETARDATION PROTEIN; METABOTROPIC RECEPTOR; POSTSYNAPTIC DENSITY PROTEIN 95; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTISM; BEHAVIOR DISORDER; CELL FUNCTION; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL ANALYSIS_IB WESTERN BLOTTING; EXPERIMENTAL LOCOMOTOR ACTIVITY TEST; FRAGILE X SYNDROME; GENE EXPRESSION; GENE INACTIVATION; INTELLECTUAL IMPAIRMENT; MALE; MAZE TEST; MOUSE; NERVE CELL; NONHUMAN; PATHOPHYSIOLOGY; POSTSYNAPTIC DENSITY; SIGNAL TRANSDUCTION; TRANSLATION REGULATION;

EID: 84896913124     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2014.00070     Document Type: Article

References (80)

1. Bassell, G. J., and Warren, S. T. (2008). Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron 60, 201-214. doi: 10.1016/j.neuron.2008.10.004.
2. Bear, M. F., Huber, K. M., and Warren, S. T. (2004). The mGluR theory of fragile X mental retardation. Trends Neurosci. 27, 370-377. doi: 10.1016/j.tins.2004.04.009
3. Berry-Kravis, E., Hessl, D., Coffey, S., Hervey, C., Schneider, A., Yuhas, J., et al. (2009). A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J. Med. Genet. 46, 266-271. doi: 10.1136/jmg.2008.063701.
4. Berry-Kravis, E., Knox, A., and Hervey, C. (2011). Targeted treatments for fragile X syndrome. J. Neurodev. Disord. 3, 193-210. doi: 10.1007/s11689-011-9074-7.
5. Berry-Kravis, E., Krause, S. E., Block, S. S., Guter, S., Wuu, J., Leurgans, S., et al. (2006). Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. J. Child Adolesc. Psychophar- macol. 16, 525-540. doi: 10.1089/cap.2006.16.525
6. Bhakar, A. L., Dolen, G., and Bear, M. F. (2012). The pathophysiology of fragile X (and what it teaches us about synapses). Annu. Rev. Neurosci. 35, 417-443. doi: 10.1146/annurev-neuro-060909-153138.
7. Brown, V., Jin, P., Ceman, S., Darnell, J. C., O'Donnell, W. T., Tenenbaum, S. A., et al. (2001). Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell 107, 477-487. doi: 10.1016/s0092-8674(01)00568-2.
8. Canitano, R. (2007). Epilepsy in autism spectrum disorders. Eur. Child Adolesc.Psychiatry 16, 61-66. doi: 10.1007/s00787-006-0563-2.
9. Choeiri, C., Staines, W. A., Miki, T., Seino, S., Renaud, J. M., Teutenberg, K., et al. (2006).Cerebral glucose transporters expression and spatial learning in the K- ATP Kir6.2(-/-) knockout mice. Behav. Brain Res. 172, 233-239. doi: 10.1016/j. bbr.2006.05.005
10. Choi, C. H., McBride, S. M., Schoenfeld, B. P., Liebelt, D. A., Ferreiro, D., Ferrick, N. J., et al. (2010). Age-dependent cognitive impairment in a Drosophila fragile X model and its pharmacological rescue. Biogerontology 11, 347-362. doi: 10. 1007/s10522-009-9259-6.
11. Clark, R. E., Broadbent, N. J., and Squire, L. R. (2005). Hippocampus and remote spatial memory in rats. Hippocampus 15, 260-272. doi: 10.1002/hipo.20056.
12. Cornish, K. M., Munir, F., and Cross, G. (1998). The nature of the spatial deficit in young females with fragile-X syndrome: a neuropsychological and molecular perspective. Neuropsychologia 36, 1239-1246. doi: 10.1016/s0028- 3932(97)00162-0
13. Cornish, K. M., Munir, F., and Cross, G. (1999). Spatial cognition in males with fragile-X syndrome: evidence for a neuropsychological phenotype. Cortex 35, 263-271. doi: 10.1016/s0010-9452(08)70799-8.
14. Darnell, J. C., Van Driesche, S. J., Zhang, C., Hung, K. Y., Mele, A., Fraser, C. E., et al. (2011). FMRP stalls ribosomal translocation on mRNAs linked to synaptic function andautism. Cell 146, 247-261. doi: 10.1016/j.cell.2011.06.013
15. de Vrij, F. M., Levenga, J., van der Linde, H. C., Koekkoek, S. K., De Zeeuw, C. I., Nelson, D. L., et al. (2008). Rescue of behavioral phenotype and neuronal protrusion morphologyin Fmr1. KO mice. Neurobiol. Dis. 31, 127-132. doi: 10. 1016/j.nbd.2008.04.002.
16. Dobkin, C., Rabe, A., Dumas, R., El Idrissi, A., Haubenstock, H., and Brown, W. T. (2000). Fmr1 knockout mouse has a distinctive strain-specific learning impairment. Neuroscience 100, 423-429. doi: 10.1016/s0306-4522(00) 00292-x
17. Dolen, G., and Bear, M. F. (2005). Courting a cure for fragile X. Neuron 45, 642-644. doi: 10.1016/j.neuron.2005.02.021.
18. Dolen, G., Osterweil, E., Rao, B. S., Smith, G. B., Auerbach, B. D., Chattarji, S., et al. (2006).Correction of fragile X syndrome in mice. Neuron 56, 955-962. doi: 10. 1016/j.neuron.2007.12.001
19. Ehrlich, I., and Malinow, R. (2004). Postsynaptic density 95 controls AMPA receptor incorporation during long-term potentiation and experience-driven synaptic plasticity. J. Neurosci. 24, 916-927. doi: 10.1523/jneurosci.4733-03.2004
20. Fatemi, S. H., and Folsom, T. D. (2011). The role of fragile X mental retardation protein in major mental disorders. Neuropharmacology 60, 1221-1226. doi: 10. 1016/j.neuropharm.2010.11.011.
21. Fu, Y. H., Kuhl, D. P., Pizzuti, A., Pieretti, M., Sutcliffe, J. S., Richards, S., et al. (1991). Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the sherman paradox. Cell 67, 1047-1058. doi: 10. 1016/0092-8674(91)90283-5.
22. Gandhi, R. M., Kogan, C. S., Messier, C., and Macleod, L. S. (2014). Visual- spatial learning impairments are associated with hippocampal PSD-95 protein dysregulation in a mouse model of fragile X syndrome. Neuroreport 25,255-261. doi: 10.1097/WNR.0000000000000087.
23. Gasparini, F., Lingenhohl, K., Stoehr, N., Flor, P. J., Heinrich, M., Vranesic, I., et al. (1999). 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 38, 1493-1503. doi: 10.1016/s0028-3908(99)00082-9.
24. Gray, N. W., Weimer, R. M., Bureau, I., and Svoboda, K. (2006). Rapid redistribution of synaptic PSD-95 in the neocortex in vivo. PLoS Biol. 4:e370. doi: 10. 1371/journal.pbio.0040370.
25. Gross, C., Berry-Kravis, E. M., and Bassell, G. J. (2012). The rapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond. Neuropsychopharmacology 37, 178-195. doi: 10.1038/npp.2011.137.
26. Hagerman, R. J. (2002). FragileXSyndrome,Diagnosis,TreatmentandResearch. 3rd Edn. Boston, MA: Johns Hopkins University.
27. Hagerman, R., Hoem, G., and Hagerman, P. (2010). Fragile X and autism: intertwined at the molecular level leading to targeted treatments. Mol. Autism 1:12. doi: 10.1186/2040-2392-1-12.
28. Hagerman, R. J. (1996). Fragile X syndrome, diagnosis, treatment and research, in Physical and Behavioral Phenotype, eds R. J. Hagerman and A. Cronister (Baltimore: Johns Hopkins University Press), 75-90.
29. Hatton, D. D., Sideris, J., Skinner, M., Mankowski, J., Bailey, D. B. Jr., Roberts, J., et al. (2006). Autistic behavior in children with fragile X syndrome: prevalence, stability and the impact of FMRP. Am. J. Med. Genet. A 140A, 1804-1813. doi: 10.1002/ajmg.a.31286.
30. Hock, B. J. Jr., and Bunsey, M. D. (1998). Differential effects of dorsal and ventral hippocampal lesions. J. Neurosci. 18, 7027-7032.
31. Hooper, S. R., Hatton, D., Sideris, J., Sullivan, K., Hammer, J., Schaaf, J., et al. 2006. Executive functions in young males with fragile X syndrome in comparison to mental age-matched controls: baseline findings from a longitudinal study. Neuropsychology 22, 36-47. doi: 10.1037/0894-4105.22.1.36.
32. Huber, K. M., Gallagher, S. M., Warren, S. T., and Bear, M. F. (2002). Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc. Natl. Acad. Sci. USA 99, 7746-7750. doi: 10.1073/pnas.122205699.
33. Jacquemont, S., Curie, A., des Portes, V., Torrioli, M. G., Berry-Kravis, E., Hagerman, R. J., et al. (2011). Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci. Transl. Med. 3, 64ra1. doi: 10.1126/scitranslmed.3001708.
34. Jarrard, L. E. (1993). On the role of the hippocampus in learning and memory in the rat. Behav. Neural Biol. 60, 9-26. doi: 10.1016/0163-1047(93)90664-4.
35. Kaufmann, W. E., Cortell, R., Kau, A. S., Bukelis, I., Tierney, E., Gray, R. M., et al. (2004).Autism spectrum disorder in fragile X syndrome: communication, social interaction and specific behaviors. Am. J. Med. Genet. A 129A, 225-234. doi: 10. 1002/ajmg.a.30229
36. Keith, D., and El-Husseini, A. (2008). Excitation control: balancing psd-95 function at the synapse. Front. Mol. Neurosci. 1:4. doi: 10.3389/neuro.02.004.2008.
37. Kogan, C. S., Bertone, A., Cornish, K., Boutet, I., Der Kaloustian, V. M., Andermann, E., et al. (2004). Integrative cortical dysfunction and pervasive motion perception deficit in fragile X syndrome. Neurology 63, 1634-1639. doi: 10.1212/01.wnl.0000142987.44035.3b
38. Kogan, C. S., Boutet, I., Cornish, K., Graham, G. E., Berry-Kravis, E., Drouin, A., et al. (2009). A comparative neuropsychological test battery differentiates cognitive signatures of fragile X and down syndrome. J. Intellect. Disabil. Res. 53, 125-142. doi: 10.1111/j.1365-2788.2008.01135.x
39. Krueger, D. D., and Bear, M. F. (2011). Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annu. Rev. Med. 62, 411-429. doi: 10. 1146/annurev-med-061109-134644.
40. Lee, I., and Kesner, R. P. (2003). Time-dependent relationship between the dorsal hippocampus and the prefrontal cortex in spatial memory. J. Neurosci. 23, 1517-1523.
41. Levenga, J., de Vrij, F. M., Buijsen, R. A., Li, T., Nieuwenhuizen, I. M., Pop, A., et al. (2011). Subregion-specific dendritic spine abnormalities in the hippocampus of Fmr1. KO mice. Neurobiol. Learn. Mem. 95, 467-472. doi: 10.1016/j.nlm.2011.02.009
42. MacLeod, L. S., Kogan, C. S., Collin, C. A., Berry-Kravis, E., Messier, C., and Gandhi, R. (2010). A comparative study of the performance of individuals with fragile X syndrome and Fmr1 knockout mice on Hebb-Williams mazes. Genes Brain Behav. 9, 53-64. doi: 10.1111/j.1601-183x.2009.00534.x
43. McBride, S. M., Choi, C. H., Wang, Y., Liebelt, D., Braunstein, E., Ferreiro, D., et al. (2005). Pharmacological rescue of synaptic plasticity, courtship behavior and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron 45, 753-764. doi: 10.1016/j.neuron.2005.01.038
44. McCormack, S. G., Stornetta, R. L., and Zhu, J. J. (2006). Synaptic AMPA receptor exchange maintains bidirectional plasticity. Neuron 50, 75-88. doi: 10.1016/j. neuron.2006.02.027
45. Mehta, M. V., Gandal, M. J., and Siegel, S. J. (2011). mGluR5-antagonist mediated reversal of elevated stereotyped, repetitive behaviors in the VPA model of autism. PLoS One 6:e26077. doi: 10.1371/journal.pone.0026077.
46. Michalon, A., Sidorov, M., Ballard, T. M., Ozmen, L., Spooren, W., Wettstein, J. G., et al. (2012). Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 74, 49-56. doi: 10.1016/j.neuron.2012.03.009.
47. Morris, R. G., Garrud, P., Rawlins, J. N., and O'Keefe, J. (1982). Place navigation impaired in rats with hippocampal lesions. Nature 297, 681-683. doi: 10. 1038/297681a0
48. Muddashetty, R. S., Kelic, S., Gross, C., Xu, M., and Bassell, G. J. (2007). Dysregu- lated metabotropic glutamate receptor-dependent translation of AMPA receptor and postsynaptic density-95 mRNAs at synapses in a mouse model of fragile X syndrome. J. Neurosci. 27, 5338-5348. doi: 10.1523/jneurosci.0937-07.2007.
49. Nakamoto, M., Nalavadi, V., Epstein, M. P., Narayanan, U., Bassell, G. J., and Warren, S. T. (2007). Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors. Proc. Natl. Acad. Sci. USA 104, 15537-15542. doi: 10.1073/pnas.0707484104.
50. Nosyreva, E. D., and Huber, K. M. (2006). Metabotropic receptor-dependent longterm depression persists in the absence of protein synthesis in the mouse model of fragile X syndrome. J. Neurophysiol. 95, 3291-3295. doi: 10.1152/jn.01316.2005
51. O'Donnell, W. T., and Warren, S. T. (2002). A decade of molecular studies of fragile X syndrome. Annu. Rev. Neurosci. 25, 315-338. doi: 10.1146/annurev.neuro.25. 112701.142909
52. Okada, K., and Okaichi, H. (2009). Functional differentiation and cooperation among the hippocampal subregions in rats to effect spatial memory processes. Behav. Brain Res. 200, 181-191. doi: 10.1016/j.bbr.2009.01.011.
53. Osterweil, E. K., Krueger, D. D., Reinhold, K., and Bear, M. F. (2010). Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome. J. Neurosci. 30, 15616-15627. doi: 10.1523/JNEUROSCI.3888-10.2010.
54. Pan, L., Woodruff, E. 3rd, Liang, P., and Broadie, K. (2008). Mechanistic relationships between Drosophila fragile X mental retardation protein and metabotropic glutamate receptor A signaling. Mol. Cell. Neurosci. 37, 747-760. doi: 10.1016/j.mcn.2008.01.003.
55. Paxinos, G., Franklin, K. B. J. (2001). The Mouse Brain in Stereotaxic Coordinates. 2nd Edn. San Diego: Academic Press.
56. Pieretti, M., Zhang, F. P., Fu, Y. H., Warren, S. T., Oostra, B. A., Caskey, C. T., et al. (1991). Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 66, 817-822. doi: 10.1016/0092-8674(91)90125-i
57. Rabinovitch, M. S., and Rosvold, H. E. (1951). A closed-field intelligence test for rats. Can. J. Psychol. 5, 122-128. doi: 10.1037/h0083542.
58. Rogers, J. L., and Kesner, R. P. (2006). Lesions of the dorsal hippocampus or parietal cortex differentially affect spatial information processing. Behav. Neurosci. 120, 852-860. doi: 10.1037/0735-7044.120.4.852.
59. Santoro, M. R., Bray, S. M., and Warren, S. T. (2012). Molecular mechanisms of fragile X syndrome: a twenty-year perspective. Annu. Rev. Pathol. 7, 219-245. doi: 10.1146/annurev-pathol-011811-132457.
60. Scerif, G., Cornish, K., Wilding, J., Driver, J., and Karmiloff-Smith, A. (2007). Delineation of early attentional control difficulties in fragile X syndrome: focus on neurocomputational changes. Neuropsychologia 45,1889-1898. doi: 10. 1016/j.neuropsychologia.2006.12.005.
61. Schnell, E., Sizemore, M., Karimzadegan, S., Chen, L., Bredt, D. S., and Nicoll, R. A. (2002). Direct interactions between PSD-95 and stargazin control synaptic AMPA receptor number. Proc. Natl. Acad. Sci. USA 99, 13902-13907. doi: 10. 1073/pnas.172511199.
62. Shore, D. I., Stanford, L., MacInnes, W. J., Klein, R. M., and Brown, R. E. (2001). Of mice and men: virtual Hebb-Williams mazes permit comparison of spatial learning across species. Cogn. Affect. Behav. Neurosci. 1, 83-89. doi: 10. 3758/cabn.1.1.83
63. Silverman, J. L., Tolu, S. S., Barkan, C. L., and Crawley, J. N. (2010). Repetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEP. Neuropsychopharmacology 35, 976-989. doi: 10. 1038/npp.2009.201
64. Snyder, E. M., Philpot, B. D., Huber, K. M., Dong, X., Fallon, J. R., and Bear, M. F. (2001). Internalization of ionotropic glutamate receptors in response to mGluR activation. Nat. Neurosci. 4, 1079-1085. doi: 10.1038/nn746.
65. Spooren, W. P., Vassout, A., Neijt, H. C., Kuhn, R., Gasparini, F., Roux, S., et al. (2000). Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J. Pharmacol. Exp. Ther. 295, 1267-1275.
66. Sturgill, J. F., Steiner, P., Czervionke, B. L., and Sabatini, B. L. (2009). Distinct domains within PSD-95 mediate synaptic incorporation, stabilization and activity-dependent trafficking. J. Neurosci. 29, 12845-12854. doi: 10. 1523/JNEUROSCI.1841-09.2009.
67. Su, T., Fan, H. X., Jiang, T., Sun, W. W., Den, W. Y., Gao, M. M., et al. (2011). Early continuous inhibition of group 1 mGlu signaling partially rescues dendritic spine abnormalities in the Fmr1 knockout mouse model for fragile X syndrome. Psychopharmacology (Berl) 215, 291-300. doi: 10.1007/s00213-010- 2130-2
68. Sullivan, K., Hatton, D., Hammer, J., Sideris, J., Hooper, S., Ornstein, P., et al. (2006). ADHD symptoms in children with FXS. Am. J. Med. Genet. A 140,2275-2288. doi: 10.1002/ajmg.a.31388.
69. Sutherland, R. J., Kolb, B., and Whishaw, I. Q. (1982). Spatial mapping: definitive disruption by hippocampal or medial frontal cortical damage in the rat. Neu- rosci. Lett. 31, 271-276. doi: 10.1016/0304-3940(82)90032-5.
70. Tauber, J. M., Vanlandingham, P. A., and Zhang, B. (2011). Elevated levels of the vesicular monoamine transporter and a novel repetitive behavior in the Drosophila model of fragile X syndrome. PLoS One 6:e27100. doi: 10. 1371/journal.pone.0027100.
71. Thomas, A., Burant, A., Bui, N., Graham, D., Yuva-Paylor, L. A., and Paylor, R. (2009). Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety. Psychopharmacology (Berl) 204, 361-373. doi: 10. 1007/s00213-009-1466-y
72. Thomas, A. M., Bui, N., Perkins, J. R., Yuva-Paylor, L. A., and Paylor, R. (2012). Group I metabotropic glutamate receptor antagonists alter select behaviors in a mouse model for fragile X syndrome. Psychopharmacology (Berl) 219, 47-58. doi: 10.1007/s00213-011-2375-4.
73. Todd, P. K., Mack, K. J., and Malter, J. S. (2003). The fragile X mental retardation protein is required for type-I metabotropic glutamate receptor-dependent translation of PSD-95. Proc. Natl. Acad. Sci. USA 100, 14374-14378. doi: 10. 1073/pnas.2336265100.
74. Turner, G., Webb, T., Wake, S., and Robinson, H. (1996). Prevalence of fragile X syndrome. Am. J. Med. Genet. 64, 196-197. doi: 10.1002/(SICI)1096- 8628(19960712)64:1 < 196::AID-AJMG35>3.0.CO;2-G
75. Van Dam, D., D'Hooge, R., Hauben, E., Reyniers, E., Gantois, I., Bakker, C. E., et al. (2000). Spatial learning, contextual fear conditioning and conditioned emotional response in Fmr1 knockout mice. Behav. Brain Res. 117, 127-136. doi: 10.1016/S0166-4328(00)00296-5.
76. Van der Molen, M. J., Huizinga, M., Huizenga, H. M., Ridderinkhof, K. R., Van der Molen, M. W., Hamel, B. J., et al. (2010). Profiling fragile X syndrome in males: strengths and weaknesses in cognitive abilities. Res. Dev. Disabil. 31, 426-439. doi: 10.1016/j.ridd.2009.10.013.
77. Van Selst, M., and Jolicoeur, P. (1994). A solution to the effect of sample size on outlier elimination. Q. J. Exp. Psychol. 47, 631-650. doi: 10. 1080/14640749408401131.
78. Yan, Q. J., Rammal, M., Tranfaglia, M., and Bauchwitz, R. P. (2005). Suppression of two major fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 49, 1053-1066. doi: 10.1016/j.neuropharm. 2005.06.004
79. Yoshii, A., Sheng, M. H., and Constantine-Paton, M. (2003). Eye opening induces a rapid dendritic localization of PSD-95 in central visual neurons. Proc. Natl. Acad. Sci. USA 100, 1334-1339. doi: 10.1073/pnas.033578 5100
80. Zhu, Z. W., Xu, Q., Zhao, Z. Y., Gu, W. Z., and Wu, D. W. (2011). Spatiotemporal expression of PSD-95 in Fmr1 knockout mice brain. Neuropathology 31, 223-229. doi: 10.1111/j.1440-1789.2010.01165.x